QNRX vs. VVOS, NRXS, PETV, CODX, PAVM, SSKN, PSTV, ALUR, BTCY, and ICU
Should you be buying Quoin Pharmaceuticals stock or one of its competitors? The main competitors of Quoin Pharmaceuticals include Vivos Therapeutics (VVOS), NeurAxis (NRXS), PetVivo (PETV), Co-Diagnostics (CODX), PAVmed (PAVM), STRATA Skin Sciences (SSKN), Plus Therapeutics (PSTV), Allurion Technologies (ALUR), Biotricity (BTCY), and SeaStar Medical (ICU). These companies are all part of the "medical equipment" industry.
Quoin Pharmaceuticals vs.
Quoin Pharmaceuticals (NASDAQ:QNRX) and Vivos Therapeutics (NASDAQ:VVOS) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, risk, dividends, institutional ownership, earnings, community ranking and profitability.
Quoin Pharmaceuticals has a beta of 1.89, meaning that its stock price is 89% more volatile than the S&P 500. Comparatively, Vivos Therapeutics has a beta of 7.31, meaning that its stock price is 631% more volatile than the S&P 500.
Vivos Therapeutics has a consensus target price of $6.10, indicating a potential upside of 123.44%. Given Vivos Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Vivos Therapeutics is more favorable than Quoin Pharmaceuticals.
8.6% of Quoin Pharmaceuticals shares are owned by institutional investors. Comparatively, 26.4% of Vivos Therapeutics shares are owned by institutional investors. 3.7% of Quoin Pharmaceuticals shares are owned by company insiders. Comparatively, 3.0% of Vivos Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
In the previous week, Quoin Pharmaceuticals had 4 more articles in the media than Vivos Therapeutics. MarketBeat recorded 6 mentions for Quoin Pharmaceuticals and 2 mentions for Vivos Therapeutics. Vivos Therapeutics' average media sentiment score of 1.44 beat Quoin Pharmaceuticals' score of 0.22 indicating that Vivos Therapeutics is being referred to more favorably in the news media.
Quoin Pharmaceuticals has a net margin of 0.00% compared to Vivos Therapeutics' net margin of -86.19%. Quoin Pharmaceuticals' return on equity of -125.60% beat Vivos Therapeutics' return on equity.
Quoin Pharmaceuticals has higher earnings, but lower revenue than Vivos Therapeutics. Vivos Therapeutics is trading at a lower price-to-earnings ratio than Quoin Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Vivos Therapeutics received 12 more outperform votes than Quoin Pharmaceuticals when rated by MarketBeat users. Likewise, 60.71% of users gave Vivos Therapeutics an outperform vote while only 55.56% of users gave Quoin Pharmaceuticals an outperform vote.
Summary
Vivos Therapeutics beats Quoin Pharmaceuticals on 11 of the 17 factors compared between the two stocks.
Get Quoin Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for QNRX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Quoin Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:QNRX) was last updated on 5/2/2025 by MarketBeat.com Staff
Buy QNRX Stock Free QNRX Stock Alerts